EyePoint Pharmaceuticals Teases August Phase 3 Wet AMD Data for DURAVYU at RBC Ophthalmology Conference

Executives from Eyepoint Pharmaceuticals (NASDAQ: EYPT) told investors at RBC Capital Markets' Ophthalmology Conference that the company's lead program, DURAVYU (vorolanib), is advancing through four Phase 3 studies in retinal disease, with the first top-line readout expected around August. Lead program and Phase 3 timeline Chief Executive Officer Jay Duker said DURAVYU is a small-molecule tyrosine